Arthneeti
Colgate-Palmolive (India) LtdQ4 FY22

Colgate-Palmolive (India) Ltd Q4 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,596.5P/E: 31.7Market Cap: ₹43.4K CrSector: Personal Products

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what Colgate-Palmolive (India) Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what Colgate-Palmolive (India) Ltd management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track Colgate-Palmolive (India) Ltd — get its next earnings analysis in your feed

How does Colgate-Palmolive (India) Ltd rank vs peers in Personal Products?

Pro feature
ThisColgate-Palmolive (India) Ltd
See where Colgate-Palmolive (India) Ltd sits in Personal ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Colgate-Palmolive (India) Ltd rank in Personal Products?

Compare Colgate-Palmolive (India) Ltd against every Personal Products company (Q4 FY22) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

Continue your research

What Colgate-Palmolive (India) Ltd's management said in earlier quarters

Others in Personal Products this season

  • Aakaar Medical (Q2 FY27)

    Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M

  • Recode Studios Ltd (Q4 FY26)

    The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…

  • Godrej Consumer Products Ltd (Q2 FY27)

    Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej

  • Anondita Medicare Ltd (Q3 FY26)

    Revenue from operations (Standalone) for H1 FY26: ₹4,765.06 lakh; H1 FY25: ₹2,497.06 lakh; YoY growth: 91% (Page 26) . Key investor presentation takeaways from

Compare:vs Godrej Consumer Products Ltdvs Dabur India Ltdvs Cupid Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →